Stereotactic radiotherapy as a valuable therapeutic procedure for controlling aldosterone-secreting adrenocortical carcinoma

• Published in: Archives of endocrinology and metabolism 2024-01, Vol.68
• Main Authors: Mermejo, Livia Mara, Zanella, Renato Heron, Cocicov, Larissa, Molina, Carlos A. Fernandes, Tucci, Silvio, Elias, Jorge, Muglia, Valdair Francisco, Viani, Gustavo Arruda, Elias, Paula C L, Moreira, Ayrton Custodio, Castro, Margaret de
• Format: Article
• Language: English
• Subjects: Case Report
• ISSN: 2359-3997; 2359-4292
• DOI: 10.20945/2359-4292-2023-0441

Aldosterone-secreting adrenocortical carcinomas (ACCs) are rare and usually present as large tumors. The only potentially curative treatment for ACC is surgical resection. However, surgery may be unfeasible in some patients who have multiple comorbidities or decline the procedure. We describe herein the case of a 44-year-old man with aldosterone-secreting ACC who declined surgery because of religious convictions. As a Jehovah’s Witness, the patient was concerned about requiring blood transfusion during surgery. Treatment with mitotane was started but interrupted due to hepatotoxicity. Subsequently, the patient was successfully treated with stereotactic ablative radiotherapy (SABR). After SABR, the patient had progressive improvement of pain, reduction in antihypertensive drugs, control of blood pressure and hypokalemia, normalization of serum aldosterone and renin levels, and reduction in tumor size and weight. To our knowledge, this is the first report of a patient with a pure aldosterone-secreting ACC who received SABR. The patient’s response was substantial, showing that SABR could be considered as an alternative local treatment for aldosterone-secreting ACCs when surgery is unfeasible.